LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

Please provide your email address to receive an email when new articles are posted on . Adalimumab yielded better outcomes than infliximab in best-corrected visual acuity, retention and other areas ...

Please provide your email address to receive an email when new articles are posted on . Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more ...

Adalimumab (Humira, AbbVie), golimumab (Simponi, Merck Sharp & Dohme) and infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Celltrion) are monoclonal antibodies that inhibit the ...

The Global Remicade (infliximab) Drug Market was valued at US$ 2405.1 Mn in 2023 and is projected to reach US$ 3697.5 Mn by 2030, at a CAGR of 5.9% during the forecast period. The Remicade Infliximab ...

Rennes, France - Patients with rheumatoid arthritis (RA) who cannot take combination therapy with infliximab (Remicade, Centocor) and methotrexate may have other safe alternatives. "Infliximab ...

NICE is recommending two new biosimilar versions of one of the world’s biggest selling drugs and says that these new and cheaper treatments should be used ahead of the original patented medicine.

Oslo, Norway - Further evidence that blocking TNF-alpha provides no benefit and could even be harmful in CHF has been provided by the final results of the ATTACH trial with infliximab (Remicade® - ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) are recommended. They are possible treatments for adults with moderate to severe ulcerative ...